The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Approaching frontline therapy selection for different risk groups in CLL
In this video, Catherine Coombs, MD, UC Irvine Health, Orange, CA, discusses frontline therapy selection for patients with chronic lymphocytic leukemia (CLL), highlighting how treatment choice may vary based on risk profile. For favorable-risk disease, Dr Coombs suggests that time-limited regimens offer advantages, including reduced cost and toxicity. She then discusses options for those with less favorable-risk disease. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
